TARGAZYME, INC.

Basic Information

*(FY14 USE 10008420)
CARLSBAD, CA, 92011-4402

Company Profile

n/a

Additional Details

Field Value
DUNS: 617462234
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: Y
Number of Employees: 8


  1. A Phase I/II Clinical Trial to Investigate Fucosylated Tregs in Prevention of GVHD

    Amount: $1,059,489.00

    DESCRIPTION provided by applicant Allogeneic hematopoietic stem cell transplant has the potential to cure various hematological malignancies and inherited disorders but is limited by treatment rel ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of HealthDepartment of Health and Human Services
  2. Therapeutic Potential and Targeted Homing of ECSOD-MSCs in Animal Model of Mucositi

    Amount: $224,932.00

    DESCRIPTION (provided by applicant): In the present submission we are requesting funding to support studies designed to assess proof-of-concept for a novel cell-based approach that possesses the poten ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Novel cell-based Restorative Approach in Treatment of Diabetes-related Retinopath

    Amount: $215,739.00

    DESCRIPTION (provided by applicant): Retinal vascular diseases remain a common cause of vision loss and blindness with diabetes as the most common condition leading to retinopathy in adults in Western ...

    SBIR Phase I 2014 Department of Health and Human Services
  4. Increased Therapeutic Potential of Migrating Neural Stem Cells and ASC101 Treatment

    Amount: $335,440.00

    DESCRIPTION (provided by applicant): Multiple sclerosis (MS) affects 1 in 1000 individuals in the US and is characterized by progressive sensory, motor and cognitive impairments. These functional defi ...

    SBIR Phase I 2013 Department of Health and Human Services
  5. ASC101 Enhancement of Regenerative Capacity of Amniotic Fluid-derived Stem Cells

    Amount: $156,754.00

    DESCRIPTION (provided by applicant): In the present STTR we propose to investigate two novel approaches in our exploration of the therapeutic and regenerative potential of cell-based medicine. Further ...

    STTR Phase I 2012 Department of Health and Human Services
  6. Enhanced Engraftment with Fucosylation of Cord Blood and Mesenchymal Stem Cells

    Amount: $290,908.00

    DESCRIPTION (provided by applicant): Three primary sources of hematopoietic stem cells (HSCs) are routinely used in HSC therapy. These include mobilized peripheral blood, bone marrow and umbilical cor ...

    SBIR Phase I 2011 Department of Health and Human Services
  7. Ex Vivo Fucosylation of Cord Blood with FTVII and Enhanced Hematopoietic Recovery

    Amount: $347,580.00

    DESCRIPTION (provided by applicant): The three primary sources of hematopoietic stem cells (HSCs) for bone marrow transplant are: mobilized peripheral blood, bone marrow, and umbilical cord. While eac ...

    SBIR Phase I 2011 Department of Health and Human Services
  8. Novel Approach to Enhance Cord Blood-Mediated Bone Marrow Homing and Engraftment

    Amount: $193,658.00

    DESCRIPTION (provided by applicant): Despite significant recent government and private-sector efforts to improve the current state of the art in bone marrow transplants, many patients still suffer fro ...

    SBIR Phase I 2008 Department of Health and Human Services
  9. Standard Robot Platform Designed for Unstructured Environment Research

    Amount: $74,516.00

    Robotic researchers currently are using insufficient and varying robot platforms to investigate issues crucial to the successful development of a remote reconnaissance tool for the urban search and re ...

    SBIR Phase I 2004 National Institute of Standards and TechnologyDepartment of Commerce
  10. A METHOD TO PREDICT SEPARATION DELAY ON AIRFOILS DUE TO VORTEX GENERATORS

    Amount: $70,000.00

    N/A

    SBIR Phase I 1996 National Aeronautics and Space Administration

Agency Micro-sites

US Flag An Official Website of the United States Government